Companies: 10,795·Total market cap: $144.5T
Kazia Therapeutics Limited

Kazia Therapeutics Limited

KZIANASDAQHealthcare● Active
$11.40
+$0.41(+3.73%)
Market Cap$18465617
P/E Ratio
52W High$17.4
52W Low$4.86
Overview

Kazia Therapeutics Limited (KZIA) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · KZIA · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-47.70kzia eps ttm · kzia earnings per shareEarnings history
PE Ratio (TTM)kzia pe ratio ttm · kzia price to earningsPE Ratio deep dive
Revenue (TTM)$2.5Mkzia revenue ttm · kzia annual revenueFull revenue history
Dividend YieldNo Dividenddoes kzia pay dividends · kzia dividend yieldDividend history
Shares Outstanding1.1Mkzia shares outstanding · kzia floatShares outstanding history
Next EarningsSep 4, 2026Est.kzia earnings date · kzia next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$42000.00▼ 98.18% YoY
202320242025
kazia therapeutics limited revenue · kzia revenue 2025
FY 2025Net Income-$20.7M▲ +22.69% YoY
202320242025
kazia therapeutics limited net income · kzia profit 2025
FY 2025EPS$-18.90▲ +65.64% YoY
202320242025
kzia eps · kazia therapeutics limited earnings per share 2025
TTM:Revenue: $2.5MNet Income: -$50.7MEPS: $-47.70View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy2 analystsis kzia a buy · kzia analyst rating
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$18.00Low
$11.40Current
$21.50Avg Target88.60% upside
$25.00High
kzia price target · kzia 12 month forecast

Total: 2 · Buy rate: 100.0%

The KZIA analyst consensus is Buy, based on ratings from 2 Wall Street analysts over the past 3 months. The average 12-month price target is $21.50, representing +88.60% upside from the current price of $11.40.

Stock Performance

Full History
1D+3.73%
1W-2.56%
1M-21.05%
3M+38.18%
YTD+65.46%
1Y+115.09%
5Y-97.77%

About Kazia Therapeutics Limited

CEOJohn Edwin Friend
IPO DateJan 6, 1999
Employees9
CountryAU

Kazia Therapeutics Limited is a biotechnology firm primarily dedicated to creating pharmaceutical treatments for cancer. Its leading therapeutic asset is Paxalisib, a distinctive small molecule that c…

what is kazia therapeutics limited · kzia stock overview · kazia therapeutics limited company profile · who is kazia therapeutics limited ceo · kzia NASDAQ · kazia therapeutics limited headquarters · kazia therapeutics limited business segments

About Stock Overview & Key Data

Kazia Therapeutics Limited (KZIA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 6, 1999. As of the latest trading session, KZIA stock price is $11.40, with a market capitalization of $18.5M. The stock has returned +115.09% over the past 12 months and +65.46% year-to-date.

According to 2 Wall Street analysts, the consensus rating for Kazia Therapeutics Limited stock is Buy, with an average 12-month price target of $21.50. In fiscal year 2025, Kazia Therapeutics Limited reported revenue of $42000.00 and net income of -$20.7M. For detailed data — including Kazia Therapeutics Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Kazia Therapeutics Limited (KZIA) stock price is $11.40. The stock is traded on NASDAQ under the ticker symbol KZIA. The 52-week range is $4.86 – $17.40.

KZIA stock priceKZIA quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice